Federal Register / Vol. 69, No. 189 / Thursday, September 30, 2004 / Notices 58543

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed:

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Phencyclidine (7471) .................... II 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company plans to produce small 

quantities of controlled substances for 

use in drug test kits. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative (CCD) 

and must be filed no later than 

November 29, 2004.

Dated: September 16, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21946 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 29, 2004, and 

published in the Federal Register on 

April 29, 2004, (69 FR 23538), Lonza 

Riverside, 900 River Road, 

Conshohocken, Pennsylvania 19428, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) for registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed below:

Drug Schedule 

Gamma hydroxybutyric acid 

(2010).

I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

The company plans to manufacture 

bulk products for the manufacture of 

finished dosage units for distribution to 

its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Lonza Riverside to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Lonza Riverside to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed.

Dated: September 8, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21950 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to section 1301.33(a) of Title 

21 of the Code of Federal Regulations 

(CFR), this is notice that on August 19, 

2004, Mallinckrodt Inc., Mallinckrodt & 

Second Streets, St. Louis, Missouri 

63147, made application by letter to the 

Drug Enforcement Administration 

(DEA) for registration as a bulk 

manufacturer of Remifentanil (9739), a 

basic class of controlled substance in 

Schedule II. 

The firm plans to manufacture the 

listed controlled substance for dosage 

form manufacture and for distribution 

in bulk form. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such as substance 

may file comments or objections to the 

issuance of the proposed registration. 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: 

Federal Register Representative, Office 

of Chief Counsel (CCD) and must be 

filed no later than November 29, 2004.

Dated: September 16, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21943 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration; 

Correction 

By Notice dated March 5, 2004, and 

published in the Federal Register on 

March 15, 2004, (69 FR 12179), 

Mallinckrodt Inc., Mallinckrodt & 

Second Streets, St. Louis, Missouri 

63147, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Morphine (9300), a 

basic class of Schedule II controlled 

substance. The drug code was 

inadvertently dropped during the 

preparation of the Notice of Registration 

dated July 28, 2004 and published in the 

Federal Register on August 18, 2004 (69 

FR 51331). 

The company plans to manufacture 

the basic class of controlled substance 

for internal use and for sale to other 

companies. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Mallinckrodt Inc. to manufacture 

Morphine is consistent with the public 

interest at this time. DEA has 

investigated Mallinckrodt Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

Morphine (9300).

Dated: September 16, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21941 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M